NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.…
Is NewAmsterdam Pharma (NAMS) Fully Priced on Book Value?
NewAmsterdam Pharma Company (NASDAQ: NAMS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 100 employees.
The shares were at 18.41 USD on 20 November 2026, down 51.9% over 52 weeks. Its 52-week range is 17.90 USD to 42.21 USD: the price is 56.4% below the high and 2.8% above the low.
Its market capitalisation is 2.21B USD.
NewAmsterdam Pharma Company reports return on equity of -29.8%.
It holds more cash than debt, a net cash position of 628.17M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 50.75 USD is 175.7% above the current price. The next earnings report is expected on 17 February 2027.